XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Stock Options and Awards
6 Months Ended
Jul. 03, 2021
Stock Options and Awards  
Note H - Stock Options and Awards

Note H - Stock Options and Awards

 

The Eastern Company 2010 Executive Stock Incentive Plan (the “2010 Plan”), for officers, other key employees, and non-employee Directors expired in February 2020. On February 19, 2020, the board of directors of the Company adopted the Eastern Company 2020 Stock Incentive Plan (the “2020 Plan”). On April 29, 2020, at the Company’s 2020 Annual Meeting of Shareholders, the shareholders of the Company approved and adopted the 2020 Plan. The 2020 Plan replaced the 2010 Plan. The Company has no other existing plan pursuant to which equity awards may be granted.

 

Incentive stock options granted under the 2020 Plan must have exercise prices that are not less than 100% of the fair market value of the Company’s common stock on the dates the stock options are granted. Restricted stock awards may also be granted to participants under the 2020 Plan with restrictions determined by the Compensation Committee of the Company’s Board of Directors. Under the 2020 Plan, non-qualified stock options granted to participants will have exercise prices determined by the Compensation Committee of the Company’s Board of Directors. During the first six months of fiscal 2021, the Company issued 24,600 stock options that were granted that were subject to the meeting of performance measurements. The Company did not issue any stock options or restricted stock in the first six months of fiscal 2020. For the first six months of fiscal 2021, the Company used several assumptions which included an expected term of 4.0 years, volatility deviation between 47.25% to 48.55% and a risk-free rate between 0.18% to 0.35% for the purposes of measuring compensation under the Black Scholes Method.

 

The 2020 Plan also permits the issuance of Stock Appreciation Rights (“SARs”). The SARs are in the form of an option with a cashless exercise price equal to the difference between the fair value of the Company’s common stock at the date of grant and the fair value as of the exercise date resulting in the issuance of the Company’s common stock. During the first six months of fiscal 2021 the Company did not issue any SARs. During the first six months of fiscal 2020 the company issued 44,000 SARs. For the first six months of fiscal 2020, the Company used several assumptions which included an expected term of 4.0 years, volatility deviation of 38.62% and a risk-free rate of 0.26% for the purposes of measuring compensation under the Black Scholes Method.

 

Stock-based compensation expense in connection with SARs previously granted to employees was approximately $100,000 and $85,000 in the second quarter of 2021 and the second quarter of 2020, respectively and was approximately $214,000 and $195,000 in the first six months of fiscal years 2021 and 2020, respectively.

 

As of July 3, 2021, there were 811,072 shares of Company common stock reserved and available for future grant under the 2020 Plan.

 

The following tables set forth the outstanding SARs for the period specified:

 

 

 

Six Months Ended

 

 

Year Ended

 

 

 

July 3, 2021

 

 

January 2, 2021

 

 

 

Units

 

 

Weighted-

Average

Exercise Price

 

 

Units

 

 

Weighted-

Average

Exercise Price

 

Outstanding at beginning of period

 

 

244,001

 

 

$21.87

 

 

 

276,000

 

 

$22.30

 

Issued

 

 

-

 

 

 

-

 

 

 

44,000

 

 

 

20.20

 

Exercised

 

 

(50,667)

 

 

19.33

 

 

 

-

 

 

 

-

 

Forfeited

 

 

(6,000)

 

 

21.20

 

 

 

(75,999)

 

 

22.00

 

Outstanding at end of period

 

 

187,334

 

 

 

22.77

 

 

 

244,001

 

 

 

21.87

 

SARs Outstanding and Exercisable

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Range of

Exercise Prices

 

Outstanding

as of July 3,

2021

 

 

Weighted

Average

Remaining

Contractual Life

 

 

Weighted

Average

Exercise Price

 

 

Exercisable

as of July 3,

2021

 

 

Weighted

Average

Remaining Contractual Life

 

 

Weighted

Average

Exercise Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

19.10 - $26.30

 

 

187,334

 

 

 

2.0

 

 

$22.77

 

 

 

87,335

 

 

 

1.0

 

 

$

22.33

 

 

The following tables set forth the outstanding stock grants for the period specified:

  

 

 

Six Months Ended

 

 

Year Ended

 

 

 

July 3, 2021

 

 

January 2, 2021

 

 

 

Units

 

 

Units

 

Outstanding at beginning of period

 

 

25,000

 

 

 

25,000

 

Issued

 

 

27,300

 

 

 

-

 

Exercised

 

 

-

 

 

 

-

 

Forfeited

 

 

-

 

 

 

-

 

Outstanding at end of period

 

 

52,300

 

 

 

25,000

 

 

As of July 3, 2021, outstanding SARs and grants had an intrinsic value of $3,105,000.